Compare CUBI & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CUBI | RCKT |
|---|---|---|
| Founded | 1994 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 394.2M |
| IPO Year | 2010 | 2014 |
| Metric | CUBI | RCKT |
|---|---|---|
| Price | $78.84 | $3.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 14 |
| Target Price | ★ $85.00 | $29.73 |
| AVG Volume (30 Days) | 201.3K | ★ 1.2M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.99 | ★ 26.37 |
| EPS | ★ 4.02 | 0.66 |
| Revenue | N/A | N/A |
| Revenue This Year | $24.95 | N/A |
| Revenue Next Year | $9.50 | $64.28 |
| P/E Ratio | $19.44 | ★ $5.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $59.34 | $2.53 |
| 52 Week High | $84.38 | $5.45 |
| Indicator | CUBI | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 48.07 | 46.09 |
| Support Level | $74.77 | $3.36 |
| Resistance Level | $79.38 | $3.65 |
| Average True Range (ATR) | 1.72 | 0.19 |
| MACD | -0.10 | -0.02 |
| Stochastic Oscillator | 55.39 | 17.08 |
Customers Bancorp Inc is a bank holding company conducting banking activities through its wholly owned subsidiary, Customers Bank. The Bank provides commercial and consumer customers the stability of a regulated financial institution supported by risk management. It serves commercial and corporate businesses nationwide, including healthcare, real estate, specialty finance, fund finance, technology and venture capital banking, mortgage finance and commercial equipment financing, and provides payments and treasury services. The Bank also serves consumers through its branch network, offering residential mortgages and personal loan and deposit products, including Banking-as-a-Service, with services delivered predominantly in Southeastern and Central Pennsylvania, New York, and other states.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.